1. Health technology

  2. •

    Biotechnology
POLYPEPTIDE GROUP AG

POLYPEPTIDE GROUP AG

54.42
USD
0.00
(0.00%)
1.15BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.78
7.33
8.06
9.25
8.5
9.15
9.65
11.06
- -
Basic EPS, GAAP
0.89
0.93
1.12
1.53
0.23
-1.45
-0.56
-0.6
- -
Free Cash Flow per Basic Share
0.17
1.29
0.23
-0.66
-2.2
-0.57
0.07
-0.89
- -
Dividend per Share
- -
- -
- -
- -
0.29
- -
- -
- -
- -
Book Value per Share
5.04
4.91
5.82
13.2
12.67
10.74
10.17
9.61
9.61
Tangible Book Value per Share
4.67
4.5
5.4
12.75
12.2
10.27
9.74
9.21
9.21
Basic Weighted Avg Shares
30
30
30
32
33
33
33
33
33
Sales/Revenue/Turnover
204
221
243
297
280
302
318
365
- -
Operating Margin (%)
15.31
16.48
19.76
22.43
4.45
-10.43
-1.77
2.22
- -
Depreciation Expense
16
17
19
21
26
28
31
35
- -
Net Income, GAAP
27
28
34
49
8
-48
-18
-20
- -
Effective Tax Rate (%)
19.13
14.87
16.85
21.04
- -
- -
- -
- -
- -
Profit Margin (%)
13.14
12.64
13.95
16.52
2.74
-15.84
-5.78
-5.4
- -
Working Capital
87
92
84
236
154
139
126
129
129
LT Debt
28
37
38
16
17
63
55
116
116
Total Equity
166
162
192
437
417
354
336
317
317
Return on Invested Capital (%)
- -
14.44
17.4
14.79
- -
- -
- -
- -
- -
Return on Capital (%)
- -
14.87
17.03
14.92
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
17
19.14
15.59
1.8
-12.39
-5.33
-6.04
- -

Capital Structure

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
34
5
5
LT Borrowings
37
74
102
LT Finance Leases
18
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
- -
- -
908

Working Capital

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
308
299
302
Cash, Cash Equivalents & STI
64
72
69
Accounts Receivable, Net
77
51
57
Inventories
137
147
144
Total Current Liabilities
183
184
174
Payables & Accruals
- -
- -
- -
ST Debt
34
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
19.41%
-5.51%
Free Cash Flow
- -
-346.71%
-1,379.92%
Net Income, GAAP
- -
-163.08%
7.24%
Sales/Revenue/Turnover
- -
8.88%
14.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
302
2024
- -
- -
- -
- -
318
2025
- -
- -
- -
- -
365

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.45
2024
- -
- -
- -
- -
-0.56
2025
- -
- -
- -
- -
-0.6

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Address
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business